Monoclonal antibody therapies against SARS-CoV-2
Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
Antibody-mediated neutralization of SARS-CoV-2
Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …
[HTML][HTML] Omicron: a heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escapes approved COVID-19 therapeutic antibodies
The new SARS-CoV-2 variant of concern “Omicron” was recently spotted in South Africa and
spread quickly around the world due to its enhanced transmissibility. The variant became …
spread quickly around the world due to its enhanced transmissibility. The variant became …
Two years into the COVID-19 pandemic: lessons learned
SJR da Silva, JCF do Nascimento… - ACS infectious …, 2022 - ACS Publications
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible
and virulent human-infecting coronavirus that emerged in late December 2019 in Wuhan …
and virulent human-infecting coronavirus that emerged in late December 2019 in Wuhan …
Regdanvimab: first approval
YY Syed - Drugs, 2021 - Springer
Regdanvimab (Regkirona™) is a recombinant human monoclonal antibody targeted against
the severe acute respiratory syndrome coronavirus 2. It is being developed by Celltrion Inc …
the severe acute respiratory syndrome coronavirus 2. It is being developed by Celltrion Inc …
Efficacy and safety of regdanvimab (CT-P59): a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate coronavirus disease …
A Streinu-Cercel, O Săndulescu… - Open forum …, 2022 - academic.oup.com
Abstract Background Regdanvimab (CT-P59) is a monoclonal antibody with neutralizing
activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report …
activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report …
SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19
C Hirsch, YS Park, V Piechotta, KL Chai… - Cochrane Database …, 2022 - cochranelibrary.com
Background Monoclonal antibodies (mAbs) are laboratory‐produced molecules derived
from the B cells of an infected host. They are being investigated as potential prophylaxis to …
from the B cells of an infected host. They are being investigated as potential prophylaxis to …
Monoclonal antibody therapies in the management of SARS-CoV-2 infection
E Miguez-Rey, D Choi, S Kim, S Yoon… - Expert Opinion on …, 2022 - Taylor & Francis
ABSTRACT Introduction Neutralizing antibodies (NAbs) that target key domains of the spike
protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have …
protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have …
Outpatient treatment of confirmed COVID-19: a living, rapid review for the American College of Physicians
I Sommer, A Dobrescu, D Ledinger, I Moser… - Annals of internal …, 2023 - acpjournals.org
An updated version of this article was published on 19 September 2023. This article has
been corrected. The original version of the article and supplement (PDF) is appended to this …
been corrected. The original version of the article and supplement (PDF) is appended to this …
Outpatient treatment of confirmed COVID-19: living, rapid practice points from the American College of Physicians (version 1)
A Qaseem, J Yost, MC Miller, R Andrews… - Annals of Internal …, 2023 - acpjournals.org
An updated version of this article was published on 19 September 2023. Description:
Strategies to manage COVID-19 in the outpatient setting continue to evolve as new data …
Strategies to manage COVID-19 in the outpatient setting continue to evolve as new data …